Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Mark M. Awad, Xinan Wang et al.|JAMA Oncology|2022Cited by 383
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerArvind Ravi, Justin F. Gainor, Matthew D. Hellmann et al.|Nature Genetics|2023Cited by 185
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V. Negrão, Sandip Pravin Patel, Haniel A. Araújo et al.|Cancer Discovery|2023Cited by 181
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung CancerBiagio Ricciuti, Mark M. Awad, Giuseppe Lamberti et al.|Journal of Clinical Oncology|2024Cited by 124
Germline variants associated with toxicity to immune checkpoint blockadeStefan Groha, Alexander Gusev, Sarah Abou Alaiwi et al.|Nature Medicine|2022Cited by 106